Pourhassan gets a compensation package equal to $1.6 million. He recently sold stock, he did not pay for, that netted him, after paying to exercise options, millions of dollars. He gets another 6 million shares if the FDA grants BTD for use of Leronlimab in tmbc.Pourhassan is, in my opinion, grossly overcompensated.

I say this as a concerned long time shareholder with a very large position in the company.

Best of luck to you.

LM